Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the long-term effect of esophagectomy in patients with esophageal squamous cell carcinoma (ESCC) by comparing the chemoradiotherapy (CRT)-only group and the trimodality treatment (TMT) group who received concurrent CRT followed by surgery. Materials and methods: We included 412 operable ESCC patients treated with TMT or CRT between January 2005 and December 2015. The oncological outcomes of the two groups were compared using a weighted Cox proportional-hazards model with inverse probability of treatment weighting (IPTW). Results: The median survival time was 64 and 32 months in the TMT (n=270) and CRT (n=142) groups, respectively (p < 0.001). After IPTW, the median overall survival (OS) remained significantly higher in the TMT group than in the CRT group (61 months vs. 32 months, p=0.016). Moreover, the TMT group showed a better local recurrence-free rate (LRFR, p < 0.001) and distant metastasis-free rate (p=0.007). In the subgroup of patients with clinical complete response (cCR), the OS was not significantly different between the two groups, both before and after IPTW adjustment (p=0.35 and p=0.93). However, among non-cCR patients, the OS was significantly higher in the TMT group (64% vs. 45%, p < 0.001). Conclusion: In patients with locally advanced ESCC, TMT was superior to CRT in terms of OS and LRFR. Such difference was more prominent in the non-cCR subgroup. In patients who achieved cCR, esophagectomy was effective in improving LRFR but not OS, suggesting that esophagectomy may be omitted in complete responders.
Abstract
Purpose: This study aimed to evaluate the long-term effect of esophagectomy in patients with esophageal squamous cell carcinoma (ESCC) by comparing the chemoradiotherapy (CRT)-only group and the trimodality treatment (TMT) group who received concurrent CRT followed by surgery. Materials and methods: We included 412 operable ESCC patients treated with TMT or CRT between January 2005 and December 2015. The oncological outcomes of the two groups were compared using a weighted Cox proportional-hazards model with inverse probability of treatment weighting (IPTW). Results: The median survival time was 64 and 32 months in the TMT (n=270) and CRT (n=142) groups, respectively (p < 0.001). After IPTW, the median overall survival (OS) remained significantly higher in the TMT group than in the CRT group (61 months vs. 32 months, p=0.016). Moreover, the TMT group showed a better local recurrence-free rate (LRFR, p < 0.001) and distant metastasis-free rate (p=0.007). In the subgroup of patients with clinical complete response (cCR), the OS was not significantly different between the two groups, both before and after IPTW adjustment (p=0.35 and p=0.93). However, among non-cCR patients, the OS was significantly higher in the TMT group (64% vs. 45%, p < 0.001). Conclusion: In patients with locally advanced ESCC, TMT was superior to CRT in terms of OS and LRFR. Such difference was more prominent in the non-cCR subgroup. In patients who achieved cCR, esophagectomy was effective in improving LRFR but not OS, suggesting that esophagectomy may be omitted in complete responders.
참고문헌 (15)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- van Hagen P, "Preoperative chemoradiotherapy for esophageal or junctional cancer", N Engl J Med, 366, pp.2074~2084 (2012)
- Sjoquist KM, "Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma : an updated meta-analysis", Lancet Oncol, 12, pp.681~692 (2011)
- Shapiro J, "Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS) : long-term results of a randomised controlled trial", Lancet Oncol, 16, pp.1090~1098 (2015)
- Stahl M, "Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus", J Clin Oncol, 23, pp.2310~2317 (2005)
- Bedenne L, "Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus : FFCD 9102", J Clin Oncol, 25, pp.1160~1168 (2007)
- Dubecz A, "Surgical resection for locoregional esophageal cancer is underutilized in the United States", J Am Coll Surg, 211, pp.754~761 (2010)
- Takeuchi H, "A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database", Ann Surg, 260, pp.259~266 (2014)
- Piessen G, "Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study", Ann Surg, 258, pp.793~799 (2013)
- Castoro C, "Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus : is surgery always necessary?", J Gastrointest Surg, 17, pp.1375~1381 (2013)
- Chao YK, "Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy", Ann Surg Oncol, 20, pp.3000~3008 (2013)
- Jeong Y, "Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma", J Surg Oncol, 109, pp.472~477 (2014)
- Yang H, "Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010) : a phase III multicenter, randomized, open-label clinical trial", J Clin Oncol, 36, pp.2796~2803 (2018)
- Xi M, "Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer : impact of histology on recurrence patterns and outcomes", Ann Surg, 269, pp.663~670 (2019)
- Markar S, "Salvage surgery after chemoradiotherapy in the management of esophageal cancer : is it a viable therapeutic option?", J Clin Oncol, 33, pp.3866~3873 (2015)